Physician profile
Ryan Griffith
NPI 1649779182
$7,783.38
in general payments reported to CMS, 2019-2025
20 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,246 · 2022: $1,934 · 2023: $1,145 · 2024: $1,984 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,097 · Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,096.98 |
| Food and Beverage | $1,506.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mid-Atlantic Surgical Systems, LLC | $3,279.22 | 2021-2025 | |
| Stryker Corporation | $2,721.91 | 2022-2025 | Mako, Blueprint Patient Specific Instrumentation, Triathlon |
| Arthrex, INC. | $652.95 | 2023-2025 | |
| Zynex Medical, INC. | $179.43 | 2025 | Nexwave |
| Depuy Synthes Sales INC. | $149.63 | 2025 | Na, Motoband, Va-Lcp |
| Becton, Dickinson and Company | $140.53 | 2022 | |
| Smith+Nephew, INC. | $130.64 | 2023-2024 | Redapt, Polarstem, Or3o Dual Mobility |
| Integra Lifesciences Corporation | $118.64 | 2023 | Tenoglide |
| Insmed, INC. | $112.27 | 2021-2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $61.05 | 2023 | |
| Pulmonx Corporation | $34.26 | 2022 | |
| Organogenesis INC. | $31.83 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $30.55 | 2023-2024 | Fasenra |
| Glaxosmithkline, LLC. | $30.19 | 2023 | Trelegy Ellipta |
| Bioventus LLC | $28.42 | 2024-2025 | Exogen Ultrasound Bone Healing System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.11 | 2023 | Stiolto Respimat |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | |
| Solventum Corporation | $15.39 | 2024 | V.A.C. Veraflo, Prevena |
| Davol INC. | $15.16 | 2023 | Arista Ah Flexitip |
| Abbvie INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.